Collaboration to facilitate an expanded manufacturing footprint to enable clinical supply of Quell’s pipeline, including QEL-001 in liver transplantation and pipeline programs in neuroinflammation and autoimmunity.
Krakow, Poland – September 06, 2021 – Selvita, one of the largest preclinical contract research organizations in Europe, announced today that it had received a grant funding of 1 M EUR to create a novel technological platform which will accelerate the drug discovery process. The grant came from the National Centre of Research and Development with a total of 1.7 M EUR dedicated to the project. The project will enable Company to implement new services for biotech and pharma clients.
Cambridge, UK,– 29 June 2021: IONTAS Limited (IONTAS), a leader in the discovery and optimization of fully human antibodies, today announces that F-star Therapeutics, Inc. (NASDAQ: FSTX), has dosed the first patients in a Phase 1 clinical trial, with FS222, a CD137/PD-L1 bispecific antibody.